U.S. markets closed

Avivagen Inc. (VIV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4050-0.0100 (-2.41%)
At close: 3:52PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4150
Open0.4150
Bid0.4050 x 0
Ask0.4150 x 0
Day's Range0.4050 - 0.4150
52 Week Range0.3900 - 0.7800
Volume92,865
Avg. Volume52,504
Market Cap23.069M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.1230
Earnings DateMar 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.94
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

      OTTAWA, Ontario, Jun 11, 2021--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares

    • Business Wire

      Avivagen to Present at LD Micro Conference Presentation on June 10th, at 10:30 A.M. EST

      Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it will be virtually presenting at the LD Micro Conference on June 10th at 10:30 A.M. Kym Anthony, Avivagen’s C.E.O., will be presenting for the company.

    • Business Wire

      Avivagen Inc. Announces Proposed Extension of Warrants and Grant of Options

      Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen" or the "Corporation"),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per shar